GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Recbio Technology Co Ltd (HKSE:02179) » Definitions » Earnings Yield (Joel Greenblatt) %

Jiangsu Recbio Technology Co (HKSE:02179) Earnings Yield (Joel Greenblatt) % : 0.00% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Jiangsu Recbio Technology Co Earnings Yield (Joel Greenblatt) %?

Jiangsu Recbio Technology Co's Enterprise Value for the quarter that ended in Jun. 2024 was HK$4,509.59 Mil. Jiangsu Recbio Technology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-573.21 Mil. Jiangsu Recbio Technology Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for Jiangsu Recbio Technology Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

HKSE:02179' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -21.93   Med: 0   Max: 0
Current: -13.02

HKSE:02179's Earnings Yield (Joel Greenblatt) % is ranked worse than
50.11% of 1329 companies
in the Biotechnology industry
Industry Median: -13.32 vs HKSE:02179: -13.02

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Jiangsu Recbio Technology Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Jiangsu Recbio Technology Co Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Jiangsu Recbio Technology Co's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Recbio Technology Co Earnings Yield (Joel Greenblatt) % Chart

Jiangsu Recbio Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
- - - -7.64 -12.12

Jiangsu Recbio Technology Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only -4.32 -7.64 - -12.12 -

Competitive Comparison of Jiangsu Recbio Technology Co's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Jiangsu Recbio Technology Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Recbio Technology Co's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangsu Recbio Technology Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Jiangsu Recbio Technology Co's Earnings Yield (Joel Greenblatt) % falls into.



Jiangsu Recbio Technology Co Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Jiangsu Recbio Technology Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-611.288/5042.97918
=-12.12 %

For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.



Jiangsu Recbio Technology Co  (HKSE:02179) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Jiangsu Recbio Technology Co Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Jiangsu Recbio Technology Co's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Recbio Technology Co Business Description

Traded in Other Exchanges
Address
No. 888 Yaocheng Avenue, Medical High-tech District, Jiangsu Province, Taizhou, CHN
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Executives
Feng Tao 2201 Interest of corporation controlled by you
Bei Jing Jun Lian Cheng Yuan Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Zhu Linan 2201 Interest of corporation controlled by you
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Qi Jia Rui Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Cheng He Zhong Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Jun Lian Jie You Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Hui Zhi Yi Hao Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Chen Hao 2201 Interest of corporation controlled by you
La Sa Jun Qi Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Chao Rui Yi Yao Ke Ji He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Lyfe Capital Fund Iii (dragon), L.p.
Liu Yong
Chen Wei 2201 Interest of corporation controlled by you
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you

Jiangsu Recbio Technology Co Headlines

No Headlines